TL;DR: Aetna, a CVS Health company, modified CPB 0544 governing immune globulin coverage for post-exposure prophylaxis, effective January 5, 2026. Here's what billing teams need to know before submitting claims for CPT 90371, 90291, 90384–90386, 90375–90377, 90389, 90288, 90393, 90396, and related HCPCS codes.
This Aetna immune globulin coverage policy update touches a broad range of post-exposure prophylaxis products — hepatitis B, CMV, Rho(D), rabies, tetanus, varicella-zoster, vaccinia, and botulism immune globulins. The policy now also explicitly requires precertification for GamaSTAN (IGIM, J1460 and J1560) across applicable commercial and Medicare Part B plans. If your team bills any of these codes for Aetna members, the criteria and precertification pathways in CPB 0544 Aetna system directly govern your reimbursement.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Immune Globulins for Post-exposure Prophylaxis |
| Policy Code | CPB 0544 |
| Change Type | Modified |
| Effective Date | January 5, 2026 |
| Impact Level | High |
| Specialties Affected | Obstetrics, transplant medicine, infectious disease, emergency medicine, hematology, pharmacy billing |
| Key Action | Confirm precertification for GamaSTAN (J1460/J1560) and verify medical necessity documentation matches CPB 0544 criteria before billing any immune globulin claims to Aetna |
Aetna Immune Globulin Coverage Criteria and Medical Necessity Requirements 2026
The Aetna immune globulin coverage policy under CPB 0544 is product-by-product, indication-by-indication. Blanket billing without matching the right diagnosis to the right globulin gets you denied. Here's how the criteria break down.
Hepatitis B Immune Globulin (CPT 90371, HCPCS J1571, J1573)
Aetna considers hepatitis B immune globulin (HBIg) medically necessary for members with HBV exposure. Covered risk groups include infants born to HBsAg-positive mothers, people with percutaneous or permucosal exposure to HBsAg-positive blood, sexual contacts of HBsAg-positive persons, and household exposure of infants under one year old to a caregiver with acute HBV infection.
Prolonged use of HBIg is covered specifically for prophylaxis of recurrent hepatitis B in HBsAg-positive liver transplant recipients — but only HepaGam B (J1573) qualifies for that transplant indication. Continuation of therapy is covered for members who continue to meet initial criteria, including new members.
Cytomegalovirus Immune Globulin (CPT 90291, HCPCS J0850)
CMV immune globulin is covered for two main scenarios: treatment of severe CMV disease in transplant recipients, and prophylaxis in specific transplant settings — CMV-negative renal transplant recipients receiving a CMV-positive donor organ, and lung, liver, pancreas, and heart transplant recipients receiving a CMV-positive donor.
CMV immune globulin is also covered for CMV pneumonitis and as adjunctive therapy with antiviral agents for ganciclovir-resistant CMV disease. Outside these indications, Aetna treats CMV immune globulin as experimental. If your transplant program bills CPT 90291 or J0850 for anything beyond these scenarios, expect a claim denial.
Rho(D) Immune Globulin (CPT 90384, 90385, 90386, HCPCS J2788, J2790)
Rho(D) coverage is the most expansive section of this policy. Aetna covers Rho(D) immune globulin for all unsensitized Rh-negative women at 24–28 weeks gestation, unless the father is known to be Rh-negative. A repeat postpartum dose is covered when an Rh-positive infant is delivered.
Rho(D) is also covered after a wide range of obstetric complications in unsensitized Rh-negative women: amniocentesis (CPT 59000), chorionic villus sampling (CPT 59015), cordocentesis (CPT 59012), ectopic pregnancy, pregnancy termination (CPT 59812–59857), fetal surgery or manipulation including external cephalic version (CPT 59412), antepartum placental hemorrhage, antepartum fetal death, miscarriage, and stillbirth.
The non-obstetric covered indication is worth noting: Rho(D) immune globulin is covered for Rho(D)-positive persons with idiopathic thrombocytopenic purpura. Bill CPT 90385 for mini-dose, 90384 for full-dose intramuscular, and 90386 for the IV formulation.
GamaSTAN and General IGIM: Precertification Now Required
The most operationally significant element of this policy update is the explicit precertification requirement for immune globulin human intramuscular injection (IGIM), sold as GamaSTAN. This applies to all Aetna participating providers in applicable plan designs.
For commercial plans, call (866) 752-7021 or fax your Statement of Medical Necessity form to (888) 267-3277. For Medicare Part B, call (866) 503-0857 or fax (844) 268-7263. GamaSTAN bills as J1460 (1 cc) or J1560 (over 10 cc). If your practice administers this product and skips precertification, you're billing without authorization — that's a straight denial.
Rabies, Tetanus, Varicella-Zoster, Vaccinia, and Botulism Immune Globulins
These products are covered when selection criteria are met. Rabies immune globulin bills as CPT 90375 (standard), 90376 (heat-treated), or 90377 (heat- and solvent/detergent-treated). Tetanus immune globulin is CPT 90389 / HCPCS J1670. Varicella-zoster immune globulin is CPT 90396. Vaccinia immune globulin is CPT 90393. Botulism immune globulin (BabyBIG) is CPT 90288.
Document the exposure event and the clinical indication clearly in the medical record. These are post-exposure prophylaxis products — the claim should reflect that context explicitly.
Aetna Immune Globulin Exclusions and Non-Covered Indications
Aetna uses the experimental, investigational, or unproven (EI&U) label broadly here. Any hepatitis B immune globulin use outside the defined risk groups is EI&U. Any CMV immune globulin use outside transplant prophylaxis, CMV pneumonitis, or ganciclovir-resistant CMV disease is EI&U.
The real issue with EI&U designations is that appeals are difficult without published clinical evidence aligned to Aetna's medical necessity standard. If your clinical team wants to use one of these products off-label, get prior authorization before treatment — not after. Retroactive authorization for EI&U indications almost never succeeds.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| HBIg for HBV-exposed individuals (defined risk groups) | Covered | CPT 90371, J1571 | Medical necessity documentation required |
| HBIg for HBsAg-positive liver transplant recipients (HepaGam B) | Covered | J1573 | HepaGam B only; prolonged use covered |
| HBIg — all other indications | Experimental/Not Covered | CPT 90371 | EI&U designation |
| CMV immune globulin — transplant prophylaxis and treatment | Covered | CPT 90291, J0850 | Specific donor/recipient CMV status required |
| CMV immune globulin — CMV pneumonitis | Covered | CPT 90291, J0850 | Adjunctive with antivirals for resistant disease |
| CMV immune globulin — all other indications | Experimental/Not Covered | CPT 90291 | EI&U designation |
| Rho(D) — antepartum prophylaxis (24–28 weeks) | Covered | CPT 90384, 90385, 90386, J2788, J2790 | Father must not be known Rh-negative |
| Rho(D) — postpartum dose (Rh-positive infant) | Covered | CPT 90384, 90385, J2790 | Repeat dose covered |
| Rho(D) — obstetric complications (amniocentesis, CVS, ectopic, termination, etc.) | Covered | CPT 90384, 90385, J2790 | Unsensitized Rh-negative women; multiple qualifying events |
| Rho(D) — idiopathic thrombocytopenic purpura | Covered | CPT 90385, J2788 | Rho(D)-positive persons only |
| GamaSTAN (IGIM) — covered indications | Covered with Precertification | J1460, J1560, CPT 90281 | Precertification required; call (866) 752-7021 (commercial) |
| Rabies immune globulin — post-exposure | Covered | CPT 90375, 90376, 90377 | Exposure event must be documented |
| Tetanus immune globulin — post-exposure | Covered | CPT 90389, J1670 | Covered when selection criteria are met |
| Varicella-zoster immune globulin | Covered | CPT 90396 | Covered when selection criteria are met |
| Vaccinia immune globulin | Covered | CPT 90393 | Covered when selection criteria are met |
| Botulism immune globulin (BabyBIG) | Covered | CPT 90288 | Covered when selection criteria are met |
Aetna Immune Globulin Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Add GamaSTAN precertification to your workflow immediately. The January 5, 2026 effective date means this requirement is already live. If your practice administers J1460 or J1560 and you haven't built precertification into your pre-service workflow, fix that today. Commercial: (866) 752-7021. Medicare Part B: (866) 503-0857. |
| 2 | Match every immune globulin claim to a specific covered indication. Generic "post-exposure prophylaxis" in the notes field isn't enough. Specify the exposure event, the immune globulin product, and the clinical risk category Aetna recognizes. For hepatitis B, document which risk group. For CMV, document the transplant type and donor/recipient CMV status. |
| 3 | Audit your Rho(D) billing for obstetric complications. The covered indication list for CPT 90384, 90385, 90386, J2788, and J2790 is long — 15+ qualifying events. Make sure your obstetrics billing team maps each clinical event to the correct CPT procedure code when Rho(D) is administered. |
| 4 | Separate your HepaGam B IV transplant claims from standard HBIg claims. J1573 (HepaGam B IV, 0.5 ml) is the only product covered for prolonged prophylaxis in HBsAg-positive liver transplant recipients. Billing J1571 (IM formulation) for that indication is a mismatch. Check your charge capture maps. |
| 5 | Use CPT 90399 (unlisted immune globulin) only when necessary — and expect scrutiny. CPT 90399 is in the covered group "if selection criteria are met," but unlisted codes trigger manual review. If a product has a specific CPT or HCPCS code in this policy, use that code. |
| 6 | Review your ICD-10-CM diagnosis code pairing. CPB 0544 maps to 378 ICD-10-CM codes. A diagnosis code mismatch between the clinical indication and the immune globulin billed is a common denial trigger. Have your billing team cross-reference active diagnosis codes against the covered indication list before claims drop. |
| 7 | Talk to your compliance officer if you're using immune globulins off-label. EI&U denials from Aetna for immune globulin are hard to overturn. If your physicians treat indications not listed in CPB 0544, involve your compliance officer and consider requesting prior authorization before the service — not after. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Immune Globulins Under CPB 0544
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Description |
|---|---|
| 90281 | Immune globulin (Ig), human, for intramuscular use |
| 90288 | Botulism immune globulin, human, for intravenous use (BabyBIG/BIG-IV) |
| 90291 | Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use |
| 90371 | Hepatitis B immune globulin (HBIg), human, for intramuscular use |
| 90375 | Rabies immune globulin (RIg), human, for intramuscular and/or subcutaneous use |
| 90376 | Rabies immune globulin, heat-treated (RIg-HT), human, for intramuscular and/or subcutaneous use |
| 90377 | Rabies immune globulin, heat- and solvent/detergent-treated (RIg-HT S/D), human, for intramuscular and/or subcutaneous use |
| 90384 | Rho(D) immune globulin (RHIg), human, full-dose, for intramuscular use |
| 90385 | Rho(D) immune globulin (RHIg), human, mini-dose, for intramuscular use |
| 90386 | Rho(D) immune globulin (RHIgIV), human, for intravenous use |
| 90389 | Tetanus immune globulin (TIg), human, for intramuscular use |
| 90393 | Vaccinia immune globulin, human, for intramuscular use |
| 90396 | Varicella-zoster immune globulin, human, for intramuscular use |
| 90399 | Unlisted immune globulin |
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Description |
|---|---|
| J0850 | Injection, cytomegalovirus immune globulin intravenous (human), per vial |
| J1460 | Injection, gamma globulin, intramuscular, 1 cc (GamaSTAN and GamaSTAN S/D) |
| J1560 | Injection, gamma globulin, intramuscular, over 10 cc (GamaSTAN and GamaSTAN S/D) |
| J1571 | Injection, hepatitis B immune globulin (HepaGam B), intramuscular, 0.5 ml |
| J1573 | Injection, hepatitis B immune globulin (HepaGam B), intravenous, 0.5 ml |
| J1670 | Injection tetanus immune globulin, human, up to 250 units |
| J2788 | Injection, Rho D immune globulin, human, minidose, 50 mcg |
| J2790 | Injection, Rho D immune globulin, human, full dose, 300 mcg |
Key ICD-10-CM Diagnosis Codes
CPB 0544 references 378 ICD-10-CM codes. The payer document provides the full list. Work with your billing team to confirm the active diagnosis codes on your claims align with the covered indication categories in CPB 0544. A diagnosis outside the covered list — even for a product that's generally covered — produces a denial.
Get the Full Picture for CPT 90371
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.